2011-2012 Influenza Season Week 16 ending April 21, 2012

All data are preliminary and may change as more reports are received.

Synopsis:

During week 16 (April 15-21, 2012), influenza activity was elevated in some areas of the United States, but declined nationally and in most regions.

• U.S. Virologic Surveillance: Of the 2,987 specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and reported to CDC/Influenza Division, 662 (22.2%) were positive for influenza.
• Pneumonia and Influenza (P&I) Mortality Surveillance: The proportion of deaths attributed to P&I was below the epidemic threshold.
• Influenza-associated Pediatric Mortality: Three influenza-associated pediatric deaths were reported. One was associated with a 2009 H1N1 virus, one was associated with a seasonal influenza A (H3) virus, and one was associated with an influenza A virus for which the subtype was not determined.
• Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness (ILI) was 1.3%, which is below the national baseline of 2.4%. Region 10 reported ILI above its region-specific baseline level. Four states experienced low ILI activity; New York City and 46 states experienced minimal ILI activity, and the District of Columbia had insufficient data to calculate ILI activity.
• Geographic Spread of Influenza: Four states reported widespread geographic activity; 10 states reported regional influenza activity; 14 states reported local activity; the District of Columbia and 21 states reported sporadic activity; Guam, the U.S. Virgin Islands, and one state reported no influenza activity, and Puerto Rico did not report.

*HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, US Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; and Region 10: AK, ID, OR, WA).
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline
‡ National data are for current week; regional data are for the most recent three weeks
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands

U.S. Virologic Surveillance:

WHO and NREVSS collaborating laboratories located in all 50 states report to CDC the number of respiratory specimens tested for influenza and the number positive by influenza type and subtype. The results of tests performed during the current week are summarized in the table below.

	Week 16
No. of specimens tested	2,987
No. of positive specimens (%)	662 (22.2%)
Positive specimens by type/subtype
Influenza A	491 (74.2%)
2009 H1N1	78 (15.9%)
Subtyping not performed	130 (26.5%)
(H3)	283 (57.6%)
Influenza B	171 (25.8%)

Predominant influenza viruses can vary by region and even between states within the same region. Seasonal influenza A (H3) viruses have predominated since the start of the 2011-2012 season nationally and in most regions, however 2009 H1N1 and influenza B viruses continue to circulate. The timing of influenza activity also can vary by region. While influenza activity may have peaked and be declining in some states or regions, other areas may not yet have reached their peak activity level. Region specific data can be found at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html
Influenza viruses circulate year-round and substantial activity may occur as late as May.

View National and Regional Level Graphs and Data | View Chart Data | View Full Screen | View PowerPoint Presentation

Antigenic Characterization:

CDC has antigenically characterized 1,291 influenza viruses [343 2009 H1N1 viruses, 745 influenza A (H3N2) viruses, and 203 influenza B viruses] collected by U.S. laboratories since October 1, 2011.

2009 H1N1 [343]

• Three hundred thirty-seven (98.3%) of the 343 viruses were characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2011-2012 influenza vaccine for the Northern Hemisphere.
• Six viruses (1.7%) tested showed reduced titers with antiserum produced against A/California/7/2009.

Influenza A (H3N2) [745]

• Six hundred six (81.3%) of the 745 viruses were characterized as A/Perth/16/2009-like, the influenza A (H3N2) component of the 2011-2012 influenza vaccine for the Northern Hemisphere.
• One hundred thirty-nine viruses (18.7%) tested showed reduced titers with antiserum produced against A/Perth/16/2009.

Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [203]:

• Victoria Lineage [85]: Eighty-five (41.9%) of the 203 influenza B viruses tested belong to the B/Victoria lineage of viruses.
• o Seventy-eight (91.8%) of these 85 viruses were characterized as B/Brisbane/60/2008-like, the influenza B component of the 2011-2012 Northern Hemisphere influenza vaccine.
• o Seven (8.2%) of these 85 viruses showed reduced titers with antisera produced against B/Brisbane/60/2008.


• Yamagata Lineage [118]: One hundred eighteen (58.1%) of the 203 influenza B viruses tested belong to the B/Yamagata lineage of viruses.

While less than 50% of U.S. influenza B viruses tested this season are similar to the influenza B component in the 2011-2012 influenza vaccine, influenza B viruses account for only 10% of influenza positive tests reported to CDC this season. Worldwide, the majority of influenza B viruses circulating have been similar to the influenza B component of the 2011-2012 Northern Hemisphere influenza vaccine.

Composition of the 2012-2013 Influenza Vaccine:

The World Health Organization (WHO) has recommended vaccine viruses for the 2012-2013 Northern Hemisphere influenza vaccines, and FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made recommendations for the composition of the 2012-2013 U.S. influenza vaccines. Both agencies recommend that the vaccine contain A/California/7/2009-like (2009 H1N1), A/Victoria/361/2011-like (H3N2), and B/Wisconsin/1/2010-like (B/Yamagata lineage) viruses. This recommendation changes the influenza A (H3N2) and influenza B virus components of the 2011-2012 Northern Hemisphere vaccine formulation. This recommendation was based on global influenza virus surveillance data related to epidemiology and antigenic characteristics, serological responses to 2011-2012 trivalent seasonal vaccines, and the availability of candidate strains and reagents.

Antiviral Resistance:

Testing of 2009 influenza A (H1N1), influenza A (H3N2), and influenza B virus isolates for resistance to neuraminidase inhibitors (oseltamivir and zanamivir) is performed at CDC using a functional assay. Additional 2009 influenza A (H1N1) clinical samples are tested for a single mutation in the neuraminidase of the virus known to confer oseltamivir resistance (H275Y). The data summarized below combine the results of both testing methods. These samples are routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be infected with an antiviral resistant virus.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 H1N1 and A (H3N2) viruses (the adamantanes do not have activity against influenza B viruses). As a result of the sustained high levels of resistance among circulating influenza A viruses, data from adamantane resistance testing are not presented in the table below.

Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2011

	Oseltamivir		Zanamivir
	Virus Samples tested (n)*	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)
Influenza A (H3N2)	1,072	0 (0.0)	1,072	0 (0.0)
Influenza B	217	0 (0.0)	217	0 (0.0)
2009 H1N1	682	15 (2.2)	393	0 (0.0)

*Includes specimens tested in national surveillance and additional specimens tested at public health laboratories in eight states (DE, FL, MD, MI, MN, NY, TX, and WA) who share testing results with CDC.

Rare sporadic cases of oseltamivir resistant 2009 H1N1 and influenza A (H3N2) viruses have been detected worldwide. Antiviral treatment with oseltamivir or zanamivir is recommended as early as possible for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at greater risk for influenza-related complications. Additional information on recommendations for treatment and chemoprophylaxis of influenza virus infection with antiviral agents is available at (http://www.cdc.gov/flu/antivirals/index.htm).

Pneumonia and Influenza (P&I) Mortality Surveillance:

During week 16, 7.0% of all deaths reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was below the epidemic threshold of 7.7% for week 16.

View Full Screen | View PowerPoint Presentation

Influenza-Associated Pediatric Mortality:

Three influenza-associated pediatric deaths were reported to CDC during week 16. One was associated with a 2009 H1N1 virus, one was associated with a seasonal influenza A (H3) virus, and one was associated with an influenza A virus for which the subtype was not determined. The deaths reported during week 16 occurred during the weeks ending March 10, 2012 (week 10), March 31, 2012 (week 13), and April 7, 2012 (week 14). This brings the total number of influenza-associated pediatric deaths reported during the 2011-2012 season to 18. Additional data can be found at: http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html

View Interactive Application | View Full Screen | View PowerPoint Presentation

Influenza-Associated Hospitalizations:

The Influenza Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-associated hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) and adults (since the 2005-2006 influenza season).

The FluSurv-NET covers more than 80 counties in the 10 Emerging Infections Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and additional Influenza Hospitalization Surveillance Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; and MI, OH, RI, and UT during the 2011-2012 season. The rates provided are likely to be a vast underestimate of the actual number of influenza-associated hospitalizations. First, the FluSurv-NET is not nationally representative, and second, influenza-associated hospitalizations can be missed, either because testing is not performed, or because cases may be attributed to other causes of pneumonia or other common influenza-related complications.

Between October 1, 2011 and April 21, 2012, 2,149 laboratory-confirmed influenza-associated hospitalizations were reported at a rate of 7.8 per 100,000 population. Among cases, 1,873 (87.2%) were influenza A, 257 (12.0%) were influenza B, and 4 (0.2%) were influenza A and B co-infections; 15 (0.7%) had no virus type information. Among those with influenza A subtype information, 749 (74.2%) were H3N2 and 254 (25.2%) were 2009 H1N1. The most commonly reported underlying medical conditions among adults were chronic lung diseases, obesity and metabolic disorders. The most commonly reported underlying medical conditions in children were chronic lung diseases, asthma and neurologic disorders. However, half of hospitalized children had no identified underlying medical conditions.

View Interactive Application | View Full Screen | View PowerPoint Presentation





View Full Screen | View PowerPoint Presentation

Outpatient Illness Surveillance:

Nationwide during week 16, 1.3% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.4%. (ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.)

View National and Regional Level Graphs and Data | View Chart Data | View Full Screen | View PowerPoint Presentation

On a regional level, the percentage of outpatient visits for ILI ranged from 0.9% to 2.4% during week 16. Region 10 reported a proportion of outpatient visits for ILI above its region-specific baseline level.

ILINet State Activity Indicator Map:

Data collected in ILINet are used to produce a measure of ILI activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI and are compared to the average percent of ILI visits that occur during spring and fall weeks with little or no influenza virus circulation. Activity levels range from minimal, which corresponds to ILI activity being below average, to intense, which corresponds to ILI activity being much higher than average. Because the clinical definition of ILI is very general, not all ILI is caused by influenza; however, when combined with laboratory data, the information on ILI activity provides a clearer picture of influenza activity in the United States.

During week 16, the following ILI activity levels were experienced:

• Four states experienced low ILI activity (Alabama, Hawaii, Idaho, and Washington).
• New York City and 46 states experienced minimal ILI activity (Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, Wisconsin, and Wyoming).
• Data were insufficient to calculate an ILI activity level from the District of Columbia.

 

*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.
Data collected in ILINet may disproportionately represent certain populations within a state, and therefore, may not accurately depict the full picture of influenza activity for the whole state.
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses, but does not measure the intensity of influenza activity.

During week 16, the following influenza activity was reported:

• Widespread influenza activity was reported by 4 states (Alaska, California, Montana, and New York).
• Regional influenza activity was reported by 10 states (Arizona, Connecticut, Kentucky, Maine, Massachusetts, Nevada, New Jersey, Rhode Island, Vermont, and Washington).
• Local influenza activity was reported by 14 states (Alabama, Colorado, Iowa, Louisiana, Michigan, Minnesota, New Hampshire, North Dakota, Ohio, Oregon, Utah, Virginia, Wisconsin, and Wyoming).
• Sporadic influenza activity was reported by the District of Columbia and 21 states (Arkansas, Delaware, Florida, Georgia, Hawaii, Illinois, Idaho, Indiana, Kansas, Maryland, Missouri, Nebraska, New Mexico, North Carolina, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, and West Virginia).
• Guam, the U.S. Virgin Islands, and one state (Mississippi) reported no influenza activity.
• Puerto Rico did not report.